Millipore Sigma Vibrant Logo

480418 NF279 - CAS 202983-32-2 - Calbiochem

A suramin analog that acts as a highly selective, competitive, and reversible ATP-antagonist of P2X receptor (IC₅₀/KB ~ 1 µM in smooth muscle).

NF279 - CAS 202983-32-2 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 8,8ʹ-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid, Na

Primary Target: P2X receptor
View Products on Sigmaaldrich.com
480418
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
202983-32-2C₄₉H₃₀N₆O₂₃S₆ · 6Na

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
480418-5MGCN
재고 정보 검색...
—
현재 재고 없음 현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      		 Plastic ampoule 5 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      —
      가격 문의
      		 —
      Description
      OverviewA suramin analog that acts as a highly selective, competitive, and reversible ATP-antagonist of P2X receptor (IC50/KB ~ 1 µM in smooth muscle). Effectively discriminates between P2Y and P2X receptors with no effect on α1A adrenoceptors, adenosine A1 and A2B receptors, histamine H1, muscarinic M3 and neuronal nicotinic acetylcholine receptors. Displays a selectivity profile of P2X1 >P2X2 >P2X3 >P2X4 (IC50 = 19 nM, 770 nM, 1.62 µM and >300 µM, respectively) in Xenopus oocytes pre-incubated with ATP. In rat and human tissues, exhibits a potency profile of rat P2X1 > human P2X1 > > rat P2X2 > rat P2X3 ~ human P2X7 > > human P2X4. Not degraded by ecto-nucleotidases.
      Catalogue Number480418
      Brand Family Calbiochem®
      Synonyms8,8ʹ-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid, Na
      References
      ReferencesKlapperstück, M., et al. 2000. Eur. J. Pharmacol. 387, 245.
      Rettinger, J., et al. 2000. Neuropharmacol. 39, 2044.
      Lambrecht, G., et al. 1999. Prog. Brain Res. 120,107.
      Damer, S., et al. 1998. Eur. J. Pharmacol. 350, R5.
      Product Information
      CAS number202983-32-2
      ATP CompetitiveY
      FormWhite solid
      Hill FormulaC₄₉H₃₀N₆O₂₃S₆ · 6Na
      Chemical formulaC₄₉H₃₀N₆O₂₃S₆ · 6Na
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetP2X receptor
      Primary Target IC<sub>50</sub>~ 1 µM as antagonist of P2X receptor in smooth muscle; 19 nM, 770 nM, 1.62 µM and <300 µM, against P2X1, P2X2, P2X3, P2X4, respectively, in Xenopus oocytes pre-incubated with ATP
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Protect from Moisture Protect from moisture
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      480418-5MGCN 04055977201352

      Documentation

      NF279 - CAS 202983-32-2 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      NF279 - CAS 202983-32-2 - Calbiochem Certificates of Analysis

      TitleLot Number
      480418

      References

      참고문헌 보기
      Klapperstück, M., et al. 2000. Eur. J. Pharmacol. 387, 245.
      Rettinger, J., et al. 2000. Neuropharmacol. 39, 2044.
      Lambrecht, G., et al. 1999. Prog. Brain Res. 120,107.
      Damer, S., et al. 1998. Eur. J. Pharmacol. 350, R5.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision11-August-2008 RFH
      Synonyms8,8ʹ-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis-1,3,5-naphthalenetrisulfonic Acid, Na
      DescriptionA suramin analog that acts as a highly selective, competitive, and reversible ATP-antagonist of P2X receptor (IC50/KB ~1 µM in smooth muscle). Effectively discriminates between P2Y and P2X receptors with no discernible effects on α1A adrenoceptors, adenosine A1 and A2B receptors, histamine H1, muscarinic M3 and neuronal nicotinic acetylcholine receptors. Displays a selectivity profile of P2X1 >P2X2 >P2X3 >P2X4 (IC50 = 19 nM, 770 nM, 1.62 µM and >300 µM, respectively) in Xenopus oocytes pre-incubated with ATP. In rat and human tissues, exhibits a potency profile of rat P2X1 > human P2X1 » rat P2X2 > rat P2X3 ~human P2X7 » human P2X4. Not degraded by ecto-nucleotidases.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number202983-32-2
      Chemical formulaC₄₉H₃₀N₆O₂₃S₆ · 6Na
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (14 mg/ml) or H₂O (35 mg/ml)
      Storage Protect from moisture
      Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
      Toxicity Standard Handling
      ReferencesKlapperstück, M., et al. 2000. Eur. J. Pharmacol. 387, 245.
      Rettinger, J., et al. 2000. Neuropharmacol. 39, 2044.
      Lambrecht, G., et al. 1999. Prog. Brain Res. 120,107.
      Damer, S., et al. 1998. Eur. J. Pharmacol. 350, R5.